The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2011Comparing Cognitive Scales in the MUSTARDD-PD Study
Objective/Rationale:
Some people with Parkinson’s may develop dementia during their disease course. Being able to detect problems with mental function at an early stage, to monitor and to reliably... -
Rapid Response Innovation Awards, 2011Testing Novel Compounds for Noninvasive Delivery of Small Interfering RNA into CNS
Objective/Rationale:
Small interfering RNA (siRNA) molecules have been successfully used to target specific genes in cell culture. However, the lack of specificity for siRNA to cells and lack of...
-
MJFF Research Grant, 2011Phenotypic Characterization of BAC LRRK2 Transgenic Pre-clinical Models
Objective/Rationale:
Mutations in the protein leucine-rich repeat kinase 2 (LRRK2) are the most common cause of inherited Parkinson’s disease (PD). Interestingly, the penetrance LRRK2 mutations and...
-
Rapid Response Innovation Awards, 2011Fractalkine-CX3Cr1 Signaling in Models of Parkinson Disease: Quest for Novel Therapeutic Strategies
Objective/Rationale:
Microglia, one of the key players in neuroinflammation, are increased in number and activated in the brains of Parkinson’s disease (PD) or pre-clinical models of PD. A recent... -
Rapid Response Innovation Awards, 2011The Development of Novel Adeno-associated Virus Vectors for Intravenous Parkinson's Gene Therapy
Objective/Rationale:
As Parkinson disease progresses, a wide range of brain areas exhibit evidence of inflammation and degeneration, but presently no therapies exist that selectively target these... -
Rapid Response Innovation Awards, 2011Developing and Characterizing Anti-Alpha-Synuclein Nanobodies from an Immune Phage Display Library
Objective/Rationale:
This project uses a novel approach to deal with alpha-synuclein, which accumulates abnormally in Parkinson’s disease (PD). Cutting-edge recombinant antibody technologies will...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.